论文部分内容阅读
目的观察血塞通注射液联合苏合香丸治疗脑梗死急性期的临床疗效及安全性。方法将93例脑梗死急性期患者随机分为对照组46例与试验组47例。对照组予以静脉滴注奥扎格雷钠注射液80 mg,bid+口服或鼻饲阿司匹林肠溶片100 mg,qd;试验组在对照组的基础上,予以静脉滴注血塞通注射液400mg,qd+口服或鼻饲苏合香丸3 g,tid。2组患者均治疗2周。比较2组患者的临床疗效、同型半胱氨酸(HCY)、超敏C反应蛋白(hs-CRP)、基质金属蛋白-9(MMP-9)以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为97.87%(46/47例)和84.78%(39/46例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组的血清HCY分别为(10.63±2.01),(15.88±2.83)μmol·L~(-1);hs-CRP分别为(4.22±0.68),(7.58±0.93)mg·L~(-1);MMP-9分别为(135.85±16.77),(187.93±20.03)mg·L~(-1),差异有统计学意义(P<0.05)。试验组出现的药物不良反应主要有白细胞升高、皮疹、恶心;对照组出现的药物不良反应主要有白细胞升高、肉眼血尿、血清肌酸酐轻度上升、恶心。试验组和对照组的药物不良反应发生率分别为6.38%和15.22%,差异有统计学意义(P<0.05)。结论血塞通注射液联合苏合香丸对脑梗死急性期的临床疗效显著,且能显著降低药物不良反应的发生率。
Objective To observe the clinical efficacy and safety of Xuesaitong injection combined with Suhexiangwan in the treatment of acute cerebral infarction. Methods A total of 93 acute cerebral infarction patients were randomly divided into control group (46 cases) and experimental group (47 cases). The control group was given intravenous injection of ozagrel sodium 80 mg, bid + oral or nasal aspirin enteric-coated tablets 100 mg, qd; the experimental group on the basis of the control group, to be given intravenous Xuesaitong injection 400mg, qd + oral Or nasal feeding Suhexiang pill 3 g, tid. Two groups of patients were treated for 2 weeks. The clinical efficacy, homocysteine (HCY), hs-CRP, MMP-9 and adverse drug reactions in two groups were compared. Results After treatment, the total effective rates of the experimental group and the control group were 97.87% (46/47 cases) and 84.78% (39/46 cases), respectively, with statistical significance (P <0.05). After treatment, the serum HCY in the test group and the control group were (10.63 ± 2.01) and (15.88 ± 2.83) μmol·L -1, respectively. The hs-CRP levels were (4.22 ± 0.68) and (7.58 ± 0.93) mg · L ~ (-1) and MMP-9 were (135.85 ± 16.77) and (187.93 ± 20.03) mg · L -1, respectively, with statistical significance (P <0.05). Adverse drug reactions occurred in the experimental group mainly leukocytosis, rash, nausea; the control group appeared adverse drug reactions are leukocytosis, gross hematuria, serum creatinine mildly increased, nausea. The incidence of adverse drug reactions in the experimental group and the control group were 6.38% and 15.22%, respectively, with significant difference (P <0.05). Conclusion Xuesaitong injection combined with Su-He-Pills significantly effect on acute cerebral infarction, and can significantly reduce the incidence of adverse drug reactions.